Association of Helicobacter Pylori Infection with Cardiovascular Diseases Subjects from Cameroon, Using GastroPanel® Serological Biomarker Panel (Pepsinogen I; Pepsinogen II; Gastrin-17; Helicobacter Pylori IgG)

Alonge Ivo Ebule1,2*, Valentine Ngum Ndze3, Ngouana Kammalac Thierry4, Guenou Etienne1,5, Chatchweng Kamtchweng Marie Felicite6, Kinkela Nzuzi Nkouma Reolayth6, Noah Noah Dominique7, Minna Maki8 and Kari Syrjanen8,9

1Faculty of Science, University of Buea, Cameroon.  
2School of Assistant Laboratory Technologies, Limbe, Cameroon.  
3Faculty of Health Sciences, University of Buea, Cameroon.  
4Antimicrobial and Biocontrol Agent Unit, University of Yaounde, Cameroon.  
5Sante (Meilleur Acces Aux Soins De Santé), Younde, Cameroon.  
6School of Laboratory Technicians Yaoundé, Cameroon.  
7Faculty of Medicine and Pharmaceuticals Sciences, University of Douala, Cameroon.  
8Department of Clinical Research, Biohit Oyj, Helsinki, Finland.  
9Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.

Authors’ contributions

This work was carried out in collaboration among all authors. Author AIE conceptualized and together with author VNN, designed the study. Authors AIE, VNN, GE, NKT, CKMF and KNNR carried out sample collection, analysis, interpreted the data and drafted the manuscript. Authors NND, MM and KS provided technical advice and corrected the manuscript. Author KS is the director of this work and responsible for the general supervision of the study. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JAMB/2021/v21i330332
Editors:
(1) Dr. Muhsin Jamal, Abdul Wali Khan University, Pakistan. 
Reviewers:
(1) Michael Dashen, University of Jos, Nigeria. 
(2) Lucie Aba Tounnou, University of Bangui, Central African Republic. 
Complete Peer review History: http://www.sdiarticle4.com/review-history/64105

Received 02 November 2020
Accepted 04 January 2021
Published 26 March 2021

*Corresponding author: E-mail: alongebule@gmail.com, alolevo@yahoo.com;
ABSTRACT

Introduction: Helicobacter pylori infection is associated with gastrointestinal diseases including atrophic gastritis and gastric cancer. Epidemiologic studies have demonstrated associations between H. pylori infection and extra gastrointestinal organ involvements including coronary artery disease and peripheral artery disease, dyslipidemia, insulin resistance and hematologic disorders. We sought to evaluate the prevalence of H. pylori infection in patients suffering cardiovascular diseases attending the Yaounde Central Hospital.

Materials and Methods: Patients suffering from various cardiovascular complications were recruited at the Yaounde Central Hospital, between January and May 2019. The clinical and sociodemographic information of the patients was recorded. Five ml of blood were collected aseptically for Pepsinogen I and II enzymes, gastrin17 hormone and IgG anti H. pylori anti-body. The test parameters were analyzed using a GastroSoft software application. The data was analyzed using Epi Info 7.0. All statistics were 95% CI. Ethical clearance was also obtained from the National Ethics Committee. The study was accepted by the authorities of the Yaounde CentralHospital. All patients signed an informed consent form.

Results: A total of 62 subjects were recruited aged 30-75 years, (mean±SD 52.03 ± 12.78 years); 34(54.84%) females aged 30 to 75 years (mean±SD 54.47 ± 13.47 years) and 28 (45.16%) males aged 30 to 65,(mean±SD 49.07± 11.44 years). Female/male ratio was 1:2. H. pylori seropisitivity occurred in 58 (93.55%) of the subjects (IgG ≥30 EIU). H. pylori seropositivity was significantly associated with high blood pressure (RR=2.2 95%C.I 1.67-2.96, p=0.024). Significantly low Triglyceride concentrations were observed in H. pylori positive (0.51±0.03g/l) compared to negative subjects (1.04 ± 0.50g/l), (p=0.03). A significant inverse correlation was observed between IgG levels and blood glucose levels (r= 0.4, p=0.004).

Conclusion: The study indicates that H. pylori infection is highly associated with various cardiovascular complications and disease risk factors.

Keywords: Helicobacter pylori infection; cardiovascular diseases; association to; gastropanel; serological biomarkers; Pepsinogen I; Pepsinogen II; Gastrin-17.

1. INTRODUCTION

Endemic non infectious diseases including cardiovascular diseases are among the most deadly diseases of the 21st century [1]. Various risk factors including hypertension, increased lipid level, obesity, diet with highfat, physical inactivity, diabetes, and stress conditions are generally associated with cardiovascular diseases (CVD) [2]. Some microorganisms have been reported to contribute in the development of cardiovascular diseases and are considered as risk factors, amongst them the spiral rod shaped gram-negative bacterium, Helicobacter pylori (H. pylori) [3,4]. Helicobacter pylori is associated withmany gastrointestinal diseases including gastritis, peptic ulcer disease, gastroesophageal reflux disease, chronic atrophic gastritis (CAG) and gastric cancer [5,6]. Helicobacter pylori infection remains high on a global scale with an estimated of 4.4 billion people infected but differs significantly among populations in various geographical regions [7]. Chronic infection with H. pylori strongly increases the risk of CAG which causes vitamin B12 deficiency that was found responsible for CVD. Because deficiency of vitamin B12 is one of the causes of hyper-homocysteinemia [3,8]. Data on the association of H. pylori and cardiovascular diseases are scarce in Cameroon. We therefore sought to evaluate the prevalence of H. pylori infection in patients with cardiovascular diseases and also find out if there exist any significant correlation between H. pylori IgG antibodies and biological markers in patients attending the Yaounde Central Hospital.

2. METHODS

2.1 Patient Information

Patients consulting for various cardiovascular complications and consented to participate were prospectively used for this study between February and May 2019 at the cardiology unit of the Yaounde Central Hospital.

2.2 Blood Samples

Basal blood was aseptically collected after at least 4 hours of fasting by venipuncture into
EDTA tubes and immediately centrifuged at 2000G for 15 minutes. The plasma samples were then distributed into cryo tubes and stored at -20 °C until analyzed. Plasma concentrations of PGI, PGII, G- 17 and H. pylori IgG determined by the Gastro Panel (Biohit plc Helsinki, Finland) (9) using the enzyme linked immunosorbent assay (ELISA), according to the manufacturer’s instructions for the measurement of absorbance after a peroxidation reaction at 450nm. The results of the GastroPanel® examination were evaluated using the Gastro Soft® interpretation software [9].

2.3 Assay Analysis

Based on the clinically-validated cut-off values for each biomarker, the software classifies the test results into one of the five categories: 1) Normal result, 2) superficial gastritis (non atrophic gastritis), H. pylori infection without atrophy 3) atrophic gastritis in the corpus, 4) atrophic gastritis in the antrum, and 5) atrophic pangastritis. The recommended cut-off values were used for all 4 biomarkers as follows: pepsinogen I(PGI) <30 μg/l, the PGI/PGII ratio <2.5, and fasting G- 17 <1 pmol/l (G-17b). Values below these cut-off levels implicate AG of the corpus (PGI, PGI/PGII) and AG of the antrum, respectively. H. pylori IgG antibody levels above 30 EIU (enzyme-immunoassay units) were considered as indicator of H. pylori infection.

2.4 Statistical Analysis

Statistical analysis was performed using the EPI Info 7.0 software package. Data were expressed as mean±SD. The differences between groups were analyzed by the Student’s t-test, Mann-Whitney U-test and Significance of differences between means was estimated with ANOVA, and between proportions using χ2 test. In all tests, values with p<0.05 were regarded statistically significant. Ethical clearance was obtained from the national ethics committee. The study was accepted by the ethics committee of the Yaounde Central Hospital. All patients signed an informed consent form.

3. RESULTS

A total of 62 patients were enrolled during the study period, aged 30-75 years (mean±SD 52.03 ± 12.78) years, including 34 (54.84%) females aged 30-75 years (mean±SD 54.47 ± 13.47) and 28 (45.16%) males aged 30-65 years (mean±SD 49.07±11.44). Among the subjects with cardiovascular diseases, 14 (22.58%) presented with heart failure, 12 (19.35%) with ischemic stroke, 10 (16.13%) had obliterating arteriopathy of the lower limbs, 08 (12.90%) with ischemic heart disease, 04 (06.45%) hypertensive encephalopathies, 04 (06.45%) coronary heart disease, 02 (03.23%) hemorrhagic stroke, 02 (03.23%) aortic dissections, 02 (03.23%) hypertrophy of the right ventricular, 02 (03.23%) cardiac tamponades and finally 02 (03.23%) with deep vein thrombosis. The results of the distribution of GastroPanel® test are summarized in Tables 1 and 2. Amongst the 62 subjects, 30 (48.39%) were interpreted as superficial gastritis (no atrophic gastritis), 32 (51.61%) were consistent with mucosal atrophy, including Atrophic Gastritis of the corpus, C (n=14 (22.58%) )PG1< 30μg/l and/or PGI/PGII<3) and (n=18, 29.39%) pangastritis, P(PGI< 30μg/l and/or PGI/PGII< 3 ; G-17< 1pmol/l). The prevalence of H. pylori in the study population was 58(93.55%). In subjects with superficial gastritis, H. pylori was responsible for 28(93.33%) and 02(6.67%) were due to either use of medication, alcohol, spices, bacterial or parasitic infection, viral infection or bile reflux as indicated by the GastroSoft. In those with atrophic gastritis, 30 (93.75%) were due to H. pylori infection and 02 (6.25%) were due to autoimmune disease.

The H. pylori seropositivity of was higher in females 32/34 (94.12%) than in males 26/28 (92.86%). This difference was not significant (X2 = 0.04; p = 0.42). The positivity rate of H. pylori infection was higher (100%) for the 30-59 age group and lower in the 70-79 age group (66.67%). There was no statistically significant difference in the prevalence of H. pylori among different age groups (X2 = 1.45; P = 0.48).

H. pylori positivity was significantly associated with patients with hypertension (RR=2.2 95% C.I 1.6-2.96 ; p=0.024); diabetics (OR=1.16 95% C.I 1.04 -1.29 ; p=0.0001), nephropathy (OR=1.16 95%C.I 1.04-1.28; p=0.0001), hyperglycemia (OR=1.21 95% C.I 1.07 -1.36 ; p=0.0001) and non smokers (X2=5.23 ; p=0.04) (Table 1).

No significant differences in mean cholesterol, HDL and LDL levels were observed between H. pylori positive and negative patients (p>0.05). A significant difference in mean Triglyceride levels in H. pylori positive and negative subjects was observed, (p=0.03) (Table 2).
Table 1. Association of *Helicobacter pylori* infection with potential risk factors

| Variable                  | *H. pylori* positive (IgG ≥ 30 EIU) 58 (93.55%) | *H. pylori* negative (IgG < 30 EIU) 4 (6.45%) | OR    | 95% CI | P-value |
|---------------------------|-------------------------------------------------|---------------------------------------------|-------|--------|---------|
| Sex                       |                                                 |                                             |       |        |         |
| Male                      | 32 (94.12%)                                      | 2 (5.88%)                                   | 0.04  |        |         |
| Female                    | 26 (92.86%)                                      | 4 (7.14%)                                   |       |        |         |
| Age group (years)         |                                                 |                                             |       |        |         |
| 33-39                     | 12 (100%)                                        | 0 (0%)                                      | 1.45  | 0.48   |         |
| 40-49                     | 16 (100%)                                        | 0 (0%)                                      | 0     |        |         |
| 50-59                     | 14 (100%)                                        | 0 (0%)                                      | 0     |        |         |
| 60-69                     | 12 (85.71%)                                      | 2 (14.29%)                                  | 3.33  |        |         |
| 70-79                     | 4 (66.67%)                                       | 2 (33.33%)                                  |       |        |         |
| Smoker                    |                                                 |                                             |       |        |         |
| No                        | 52 (96.30%)                                      | 2 (3.70%)                                   | 5.23  |        |         |
| Yes                       | 6 (75.00%)                                       | 2 (25.00%)                                  |       |        |         |
| Diabetic                  |                                                 |                                             |       |        |         |
| No                        | 50 (92.59%)                                      | 4 (7.41%)                                   | Ref   | 1.16   | 0.04-1.29 |
| Yes                       | 8 (100%)                                         | 0 (0%)                                      | OR    |        |         |
| Hyperglycemic              |                                                 |                                             |       |        |         |
| No                        | 48 (92.31%)                                      | 4 (7.69%)                                   | Ref   | 1.16   | 0.04-1.29 |
| Yes                       | 10 (100%)                                        | 0 (0%)                                      | OR    |        |         |
| Nephrotic syndrom         |                                                 |                                             |       |        |         |
| No                        | 50 (92.59%)                                      | 4 (7.41%)                                   | Ref   | 1.16   | 0.04-1.29 |
| Yes                       | 8 (100%)                                         | 0 (0%)                                      | OR    |        |         |
| Hypertensive              |                                                 |                                             |       |        |         |
| No                        | 26 (86.67%)                                      | 4 (13.33%)                                  | Ref   | 95% C.I | 0.024   |
| Yes                       | 32 (100%)                                        | 0 (0%)                                      | RR    | 2.2    | 1.6-2.96 |

Table 2. Mean CHO, TG, BS, HDL and LDL levels (± SD) according to *Helicobacter pylori* serostatus

| Variable | H. Pylori | Atrophic class |
|----------|-----------|----------------|
|          | Negative IgG<30EIU | Positive IgG≥30EIU | p-value | AGPan | AGC | S | p-value |
| CHO (g/L) | 01.84±0.59 | 1.82±0.31 | 0.93 | 01.89±0.65 | 1.91±0.67 | 1.77±0.49 | 0.68 |
| TG (g/L)  | 1.04 ± 0.50 | 0.51 ± 0.03 | 0.03 | 0.88±0.43 | 1.06±0.42 | 1.05±0.56 | 0.47 |
| HDL (g/L) | 0.53 ± 0.21 | 0.59 ± 0.25 | 0.59 | 0.61±0.19 | 0.64±0.22 | 0.43±0.16 | 0.0008 |
| LDL (g/L) | 1.26 ± 0.45 | 1.18 ± 0.23 | 0.71 | 1.19±0.41 | 1.24±0.38 | 1.30±0.48 | 0.66 |

AGPan, atrophic gastritis of antrum and corpus; AGC, atrophic gastritis of the corpus; CHO, total cholesterol; TG, triglycerides; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; g/L, gram per litre

4. DISCUSSION

Several studies have reported a significant association between *H. pylori* infection and extragastric diseases such as coronary heart disease, dyslipidemia, hematological disorders and arteriosclerosis [2,10].

The results of GastroPanel® are presented in table 1 and 2. In this analysis of the biomarker profile of GastroPanel, atrophic gastritis appeared in 32 (56.61%) of the subjects (PGI<30 μg / l) and hypochlorhydria in 36 (58.06%) (G-17>10 pmol / l) of the subjects. The results show that the prevalence of *H. pylori* infection was 58 (93.55%). This prevalence is in line with that reported in several studies on patients with cardiovascular disease e. g. [2] (80.2%), [11] (78.8%). This prevalence is also similar to those previously reported in dyspeptic patients [12] (81.40%), [13] (79.80%) and in diabetic subjects in Cameroon [14] (88.2%). However, our results contrast sharply with those reported by [15] (29.5%) using the PCR test, [15] (23.8%) using
antibodies against immunoglobulin A (IgA) and [15] (53.3%) using antibodies against immunoglobulin G (IgG). This may be as a result of diagnostic technique used. Several possible mechanisms and pathways have been described as to how \textit{H. pylori} contribute to cardiovascular complications [10]. Repeated exposure to infection leads to failure of the inflammatory process and inability to control the progress of infectious agents that leads to a number of diseases such as heart disease and cancer [16,17]. Chronic stimulation due to bacterial infection in the gastric mucosa produces more induction of dyslipidemia, increases fibrinogen levels, stimulates the release of reactive protein and hyperhomocysteinemia leading to artery blockage and the development of heart problems [3]. Also, chronic infection with \textit{H. pylori} is known to increase pH levels, increase gastric juice and decrease ascorbic acid levels, which will cause a reduction in folate absorption and thus increase the concentration of homocysteine that causes endothelial cell damage [18]. In addition, atrophic gastritis and hypochlorhydria observed in these subjects are a risk of enteric infections, low absorption of ATBs, vitamin B12 and some divergent micronutrients, including iron, calcium, magnesium and zinc, with an increased risk of clinically important sequelae, such as cognitive disorders, neurodegenerative and vascular disorders, encephalopathies, anemia and osteoporosis [19,20]. We found no association between \textit{H. pylori} seropositivity with males (92.86%) and females (94.11%), (p=0.42). Similarly, no significant association (p=0.48) between \textit{H. pylori} and age groups in patients with cardiovascular disease was observed, however, most diseases related to \textit{H. pylori} are associated with males [21,22]. We observed a significant association between \textit{H. pylori} seropositivity and hypertensive subjects (OR=2.2, 95% C.I 1.6 -2.96, p=0.024), diabetics (OR=1.16 95% C.I 1.04 -1.29, p=0.0001), nephropathy (OR=1.16 95% C.I 1.04-1.28, p=0.0001) and hyperglycemic subjects ((OR=1.21 95% C.I 1.07 -1.36, p=0.0001) (Table 1). It has been shown that \textit{H. pylori} infection is involved in the regulation of 2 hormones leptin and ghrelin involved in energy hemostasis and their interaction affects obesity, insulin sensitivity and and glucose hemostasis [23]. We have previously demonstrated a strong association between \textit{H. pylori} infection and Diabetes mellitus type 2 subjects [14]. No significant differences in mean cholesterol, HDL and LDL levels were observed between \textit{H. pylori} positive or negative patients (p>0.05). A significant difference in mean Triglyceride levels in \textit{H. pylori} positive and negative subjects was observed, (p=0.03) (Table 2). [24] found significant differences between triglyceride and HDL values among \textit{H. pylori} seropositive vs seronegative subjects. [25] did not observe any significant differences in plasma cholesterol, or triglyceride levels among seropositive and seronegative patients. The low triglyceride and cholesterol levels observed in our study disagreed with [2,26]. This difference may be due to the fact that our patients were followed nutritionally and therapeutically. \textit{H. pylori} infection induces an increase in cholesterol and triglyceride levels with a decrease in HDL cholesterol contributing to the development of dyslipidemia, a well-known cardiovascular risk factor [26].

5. CONCLUSION
The study indicates that \textit{H. pylori} infection is highly associated with various cardiovascular complications and disease risk factors. Thus, patients suffering from various cardiovascular diseases are at risk of gastric cancer and require continuous monitoring.

DISCLAIMER
The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT AND ETHICAL APPROVAL
Ethical clearance was obtained from Center Regional Committee for Research on Human Health (CRERSH). An authorization was obtained the authorities of the Jamot Hospital of Yaounde. All patients signed an informed consent form.

AVAILABILITY OF DATA AND MATERIALS
All data used during the current study are available from the corresponding author on reasonable request.
ACKNOWLEDGEMENT

We thank the staff of the Haematology unit of the General Hospital of Yaounde for their technical assistance.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Kucukazman M, Yeniova O, Dal1 K, Yavuz B. Helicobacter pylori and cardiovascular disease. European Review for Medical and Pharmacological Sciences. 2015;19: 3731-3741.
2. Prasad GJ, Surendra GG, Shaikh AF. Helicobacter pylori and cardiovascular complications: A mechanism based review on role of Helicobacter pylorin cardiovascular diseases. Integrative Medicine Research. 2016;5:244–249.
3. Aksoy H, Sebin SO. H. pylori and Cardiovascular Diseases. Gen Med (Los Angel). 2015;S1:1000S1-007. DOI: 10.4172/2327-5146.1000S1-007.
4. Malfertheiner P, Marino V, Christian S. Helicobacter pylori Infection. New Facts in Clinical Management. Curr Treat Options Gastro; 2018. DOI: 10.1007/s11938-018-0209-8
5. Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva L, Syjrânen K. Prevalence of H. pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers. Anticancer Research. 2013;33(10):4595-602.
6. Ebule IA. GastroPanel For The Diagnosis Of Gastritis: A Tool For Health Emmergence NYA Publishers. 2016;1:1-82.
7. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9. DOI: org/10.1053/j.gastro.2017.04.022.
8. Redén S, Ryberg A, Petersson F, Eriksson O, Nägga K, et al. Homocysteine levels in chronic gastritis and other conditions: Relations to incident cardiovascular disease and dementia. Dig Dis Sci. 2010;55:351-358.
9. Available:http://www.biohithealthcare.com/products/diagnostics-tests/products/1/gastropanel.
10. Jamshid V, SeyyedFH, Vahid D, Mostafa V, Mohammadamin S, Mohammadreza S. Association of Helicobacter pylori Infection with Coronary Artery Disease: Is Helicobacter pylori a Risk Factor? The Creative Commons Attribution License; 2014.
11. Vcev A, Nakic D, Mrden A. Helicobacter pylori infection and coronary artery disease, Collegium Antropoligicum. 2007; 31(3):757–760.
12. Noah Noah D, Assoumou OMK, Bagnaka S, Ngaba GP, Alonge IE, et al. Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and Helicobacter pylori infection. Open J Gastroenterol. 2012; 2:113-118.
13. Ebule IA, Longdoh AN, Palermo IL. Helicobacter pylori infection and atrophic gastritis. Afr Health Sci. 2013;13:112-117.
14. Ebule IA, Djune FAK, Njembosay BA, Doh GN, Metaghue G, et al. Association of Helicobacter Pylori Infection and Diabetes Mellitus Type 2 Subjects in Yaounde Cameroon Using a Panel of Serum Biomarkers (PGII, HplgG): A Case Control Study. J Clin Gastroenterol Treat. 2017;3:053. DOI: org/10.23937/2469-584X/1510053
15. Izadi M, Fazel M, Sharubandi S. Helicobacter species in the atherosclerotic plaques of patients with coronary artery disease, Cardiovascular Pathology. 2012; 21(4):307–311.
16. AL-Obeydi ES, Saeed BN. Helicobacter pylori in Iraq patient with ischemic heart disease. Fac Med Baghdad. 2011;53:29–31.
17. Vareki SM, Zarkesh-Esfahani H, Behjati M. Helicobacter pylori’s evasion of the immune system could establish an inflammatory environment that potentially induces the development of coronary artery disease. Jundishapur J Microbiol. 2013;6:243–7.
18. Corrado E, Novo S. Role of inflammation and infection in vascular disease. Acta Chirurgica Belgica. 2005;105(6):567–579.
19. Agréus L, Kuijpers EJ, Kucpinkskas L, Malfertheiner P, Di Mario F, Loja M, Mahachai V, Yaron N, Van Oijen M, Perez
Perez G, Rugge M. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scandinavian journal of gastroenterology. 2012;47(2):136-47.

20. Sipponen P, Maaroos Hl. Chronic gastritis. Scandinavian Journal Gastroenterol. 2015 3;50(6):657-67.

21. International Agency for Research on Cancer, World Health Organization. Schistosomes, Liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to human. Monogr. Eval. Carcinog. Risks Hum. 1994;61:218-20.

22. De Martel C, Parsonnet J. Helicobacter pylori infection and gender: A meta-analysis of population-based prevalence surveys. Dig Dis Sci. 2006;51:2292-2301.

23. Francois F, Roper J, Joseph N, Pei Z, Chhada A, Blaser MJ et al. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol. 2011;11:37.

24. Niemelä S, Karttunen T, Korhonen T, Läärää E, Karttunen R, Íkäheimo M, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart. 1996;75:573-5.

25. Regnström J, Jovinge S, Bavenholm P, Ericson C, De Faire U, Hamsten A, et al. Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease. J Int Med. 1998;243:109-13.

26. Alejandra MT, Miguel MG. Helicobacter pylori: A New Cardiovascular Risk Factor? Rev Esp Cardiol. 2002;55(6):652-6.